Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.41 is 235% below its 5-year average of -0.72, near the low end of its 5-year range (-2.77–3.19).
1247.62% below its 12-month average of 0.21.
Reported quarterly EPS; no daily interpolation. Q1 FY2027 (2026-07-31): -0.54.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:57:51.018Z. Historical observations retain their original dates. Historical series through 2025-09-15.
EARNINGS PER SHARE (EPS)
-2.41
EARNINGS PER SHARE (EPS) AVG TTM
0.21
EARNINGS PER SHARE (EPS) AVG 3Y
-0.40
EARNINGS PER SHARE (EPS) AVG 5Y
-0.72
EARNINGS PER SHARE (EPS) AVG 10Y
-4.06
EARNINGS PER SHARE (EPS) AVG 15Y
-4.55
EARNINGS PER SHARE (EPS) AVG 20Y
-14.85
CURRENT VS TTM AVG
-1247.62%
CURRENT VS 3Y AVG
-502.50%
CURRENT VS 5Y AVG
-234.72%
CURRENT VS 10Y AVG
+40.61%
CURRENT VS 15Y AVG
+47.00%
CURRENT VS 20Y AVG
+83.77%
PharmaCyte Biotech, Inc.
Market Cap
$4.71M
Earnings Per Share (EPS)
-2.41
TTM Avg
0.21
3Y Avg
-0.40
5Y Avg
-0.72
Market Cap
$4.66M
Earnings Per Share (EPS)
-6.95
TTM Avg
-22.18
3Y Avg
-69.66
5Y Avg
-91.58
Market Cap
$4.94M
Earnings Per Share (EPS)
-1.19
TTM Avg
-2.08
3Y Avg
-2.84
5Y Avg
-5.63
Market Cap
$4.51M
Earnings Per Share (EPS)
-4.39
TTM Avg
-44.24
3Y Avg
-644.57
5Y Avg
-610.60
Market Cap
$4.92M
Earnings Per Share (EPS)
-3.64
TTM Avg
-254.03
3Y Avg
-3442.01
5Y Avg
-5629.67
Market Cap
$5.00M
Earnings Per Share (EPS)
-23.70
TTM Avg
-20.75
3Y Avg
-13.28
5Y Avg
-9.32
Market Cap
$5.02M
Earnings Per Share (EPS)
-4.53
TTM Avg
-13.96
3Y Avg
-30.40
5Y Avg
-166.98
Market Cap
$5.02M
Earnings Per Share (EPS)
-5.32
TTM Avg
-8.47
3Y Avg
-12.67
5Y Avg
-14.30
Market Cap
$5.03M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.61
3Y Avg
-0.43
5Y Avg
-0.43
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.71M | -2.41 | 0.21 | -0.40 | -0.72 |
| CalciMedica, Inc. (CALC)vs › | $4.66M | -6.95 | -22.18 | -69.66 | -91.58 |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.94M | -1.19 | -2.08 | -2.84 | -5.63 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | -4.39 | -44.24 | -644.57 | -610.60 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.92M | -3.64 | -254.03 | -3442.01 | -5629.67 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | -23.70 | -20.75 | -13.28 | -9.32 |
| Imunon, Inc. (IMNN)vs › | $5.02M | -4.53 | -13.96 | -30.40 | -166.98 |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.02M | -5.32 | -8.47 | -12.67 | -14.30 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | N/A | -1.61 | -0.43 | -0.43 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | -9.39 | -11.95 | -11.32 | -8.88 |
Trailing EPS (TTM)
$-2.41
Forward EPS (Est.)
$-45.00
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2026-04-30 | -2.77 |
| 2025-04-30 | 3.19 |
| 2024-04-30 | -1.80 |
| 2023-04-30 | -0.22 |
| 2022-04-30 | -0.27 |
| 2021-04-30 | -2.45 |
| 2020-04-30 | -4.23 |
| 2019-04-30 | -5.55 |
| 2018-04-30 | -10.57 |
| 2017-04-30 | -7.88 |
| 2016-04-30 | -12.09 |
| 2015-04-30 | -21.14 |
| 2014-04-30 | -70.09 |
| 2013-04-30 | -5.44 |
| 2012-04-30 | -7.60 |
| 2011-04-30 | -5.98 |
| 2010-04-30 | -29.81 |
| 2009-04-30 | -44.98 |
| 2008-04-30 | -33.86 |
| 2007-04-30 | -33.36 |
| 2006-04-30 | -102.95 |
| 2005-04-30 | -61.74 |
| 2004-04-30 | -27.40 |
| 2003-04-30 | -0.55 |
| 2002-04-30 | -0.51 |
